Better cell cultures lower your research costs!-A common Neuromics' theme is harnessing the power of cells. The raw cost of the cells are often the biggest consideration. We encourage our customers to focus on true costs. These include the # number of cells (how many times can they be passaged?), culture viability (how long do the cells live) and bioactivity (how closely do cultures mimic in vivo behavior?). I would like to present a publication and presentation confirms our competitiveadvantage when analyzing true costs.

1. Harnessing the Power of
CellsTM
New Assays for
Musculoskeletal Disorders Drug
Discovery
Executive Overview
1

2. Solutions for Musculoskeletal Disease Research
Potent Umbilical Cord Blood Derived Human Mesenchymal Stem Cells
 Alternative to induced pluripotent and embryonic stem cells
 Phenotypically and morphologically stable through 50 population doublings
 i.e. CD44, CD45,CD71 and CD105 expressing.
 Capacity to produce cell numbers required for high throughput
& content screening
Differentiated Cells: Osteoblasts, Chondrocytes and Fibroblasts
Potent Media
 Low serum and clinical grade, serum
free expansion media
 Osteogenesis, chondrogenesis &
adipogenesis media
 Stem cell basal media
MSCGroTM Media vs Lonza
1 4/30/2013 2

3. Potent Cells and Media-Better Results=Lower Costs
2 4/30/2013 3
Our Media Keeps your Cells Going and Going “We tested the
effects of MSCTMGro defined medium using several different
lots of human adult primary stem cells and found that
MSCGro supports a more robust proliferation rate than
normal undefined media. This provided shorter doubling
times and increased cellular yield, and maintained the cells in
an undifferentiated state. We also found that MSCGro
medium is stable under normal laboratory conditions for an
extended time period compared to other defined media.” Ben
Buehrer, VP and CSO, Zen-Bio
Images: (A) Human cord-blood MSCs were expanded in
low-serum MSC-GroTM to confluence as shown here. (B)
were differentiated in osteogenic MSC-GroTM. Early stage
osteoblasts are shown here; the arrow shows early
formation of mineralized matrix. (C)&(D) Mature
osteoblasts stained positive for Alizarin red. Phase contrast
image at 200 x, scale bar is 50 mmeters.

4. Potent Cells and Media-Summary
3 4/30/2013 4
Cells are differentiated from human MSCs-
Competitive to IPSCs since there is no
reprogramming nor epigenetic issues intrinsic to
IPSCs
Cost-effective due to manufacturing scalability
Direct purchase without licensing requirement
Highly experienced team with extensive technical and
biopharma partnership experience.
Cell therapy application as well as discovery.

5. Capabilities meet HCS/HTS Requirements
 Cost-effective materials to meet target per well costs
 Human cells reduce false positives vs. animal tissues
 Cells express proteins of interest. Verification assays provided
based on specific requirements.
 Readily scalable: Identical phenotype/genotype from pilot to
screening mode.
 Co-culture capability for custom assays.
 E.g., chondrocyte/osteoblasts
4 4/30/2013 5

6. Evaluation Process
 Confidential discussion of Specific Disorder, Therapeutic Target(s) and cell
based assay requirements.
 Design pilot assay with deliverables and milestones
 Review milestone data vs requirements
 Revise assay as needed
 Determine final assay configuration.
 Determine scale up requirements
 Cost targets
 Material and deliverables
 Evaluate progress vs plans and adjust accordingly
 Position capabilities for future projects
5 4/30/2013 6

7. Contacts
Technical and Consulting:
Dr. Jim Musick
President
Vitro Biopharma
jim@vitrobiopharma.com
(303) 999-2130
4621 Technology Drive
Golden, CO 80403
Sales/Proposal Process
Pete Shuster
CEO
Neuromics
pshuster@neuromics.com
612-801-1007
5325 West 74ths Street
Edina, MN 55439
Draft 1 04-2013-3 7